Tenax Therapeutics shares surge 10.48% after-hours as positive BSSR results and initiation of LEVEL-2 trial boost confidence.

Tenax Therapeutics surged 10.48% in after-hours trading following the announcement of favorable clinical trial updates. The company confirmed its ongoing Phase 3 LEVEL study remains adequately powered at over 90% to detect a 25-meter improvement in 6-minute walk distance, eliminating the need to increase enrollment. Enrollment is on track for completion by mid-2026, with topline data expected in late 2026. Additionally, Tenax initiated the global Phase 3 LEVEL-2 trial for TNX-103 in pulmonary hypertension patients, targeting 540 participants, and announced plans for a long-term open-label extension study. These developments reinforced investor confidence in the drug’s regulatory and commercial potential, particularly as no approved therapies currently exist for PH-HFpEF. The positive data and expanded clinical pipeline directly aligned with the stock’s sharp after-hours rise.